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Introduction {#sec1}
============

Arginine methylation, a post-translational modification, is found in a broad range of proteins, including histones, transcription factors, membrane proteins, and RNA-binding proteins (RBPs) ([@bib69]). In mammalian cells, 10 protein arginine methyltransferases (PRMTs) are responsible for arginine methylation and have been classified into three groups according to their catalytic machinery ([@bib69], [@bib30]). PRMT1, PRMT2, PRMT3, PRMT4 (also called CARM1), PRMT6, PRMT8, and METTL23 belong to type I PRMTs, which catalyze the formation of mono-methylarginine and asymmetric dimethylarginine. PRMT5 and PRMT9 are known as type II PRMTs, which are capable of producing mono-methylarginine and symmetric dimethylarginine ([@bib27], [@bib70]). PRMT7 has been characterized as a type III enzyme synthesizing only mono-methylarginine ([@bib74]).

PRMT1, a ubiquitously expressed type I enzyme, was the first identified PRMT, and it regulates a wide variety of cellular processes, such as transcription, DNA damage response, and signal transduction ([@bib64], [@bib68], [@bib69]). The *in vivo* functions of PRMT1 were not identified in mammals for a long time, because conventional PRMT1-deficient mice showed early embryonic lethality ([@bib55]). In recent years, two independent reports using heterozygous *Prmt1*-deficient mice revealed that PRMT1 controls hepatic gluconeogenesis and neuronal excitability in the CNS ([@bib14], [@bib38]). Another group reported that lack of PRMT1 in murine muscle stem cells impairs muscle regeneration ([@bib8]). On the other hand, we demonstrated that CNS-specific PRMT1-deficient mice exhibited hypomyelination, indicating a vital role of PRMT1 in oligodendrocyte development ([@bib29]). Furthermore, we also showed that loss of PRMT1 in vascular endothelial cells results in angiodysplasia in mouse embryo ([@bib34]). Thus, an increasing number of studies indicate that PRMT1 has crucial roles in multiple tissue functions and development.

Several reports have investigated the protein expression levels of PRMTs in the rodent heart and show that the cardiac tissue expresses PRMT1, PRMT3, PRMT4, PRMT5, and PRMT7 ([@bib10]). In addition, PRMT5 directly methylates GATA4 transcription factor, and inhibits phenylephrine-induced cardiomyocyte hypertrophy in neonatal rat ventricular myocytes ([@bib12]). PRMT4 has been shown to regulate aging-related autophagy in mouse heart ([@bib42]). Interestingly, cardiac PRMT1 expression is increased in patients with coronary artery disease and in rats with isoproterenol-induced heart failure ([@bib13], [@bib45]), suggesting the importance of PRMT1 in the heart. However, the physiological function of PRMT1 in the heart remains to be elucidated.

A number of reports have demonstrated that genetic deletion of RBP causes abnormal alternative splicing, resulting in lethal heart failure ([@bib67], [@bib26], [@bib71], [@bib65]). SRSF1, a serine/arginine-rich family of splicing factors, is essential for the splicing switch of the Ca^2+^/calmodulin-dependent kinase II δ (*Camk2d*) gene, and its deficiency in mouse cardiomyocytes leads to dilated cardiomyopathy (DCM) ([@bib67]). Moreover, mutations in RNA-binding motif protein 20 (RBM20) gene, a regulator of titin (*Ttn*) mRNA splicing, has been shown to cause human DCM ([@bib26], [@bib66], [@bib5]). Other reports have shown that hnRNP U and RBFOX2 are necessary for alternative splicing of some genes and maintenance of cardiac function in mouse models ([@bib71], [@bib65]). Interestingly, using a proteomic approach, it has been shown that many types of RBPs, such as SRSFs, RBMs, hnRNPs, and RBFOXs, are methylated in the arginine residues ([@bib25]). Although it has been reported that PRMT1 methylates various RBPs, including hnRNP A2, hnRNP U, and RBM15 ([@bib52], [@bib32], [@bib73]), there is no *in vivo* evidence that PRMT1 regulates alternative splicing.

In this study, we aimed to assess whether the deletion of PRMT1 affects cardiac functions and alternative splicing events in the heart. To this end, we generated cardiomyocyte-specific PRMT1-deficient mice and found that they display features of heart failure, including contractile dysfunction and cardiac chamber dilation. Furthermore, we also found that the deletion of PRMT1 impairs alternative splicing of mRNA in the heart and detected uncharacterized alternative splicing isoforms in some genes. Finally, we demonstrated that protein products translated from alternatively spliced mRNA variants exhibit distinct ubiquitination status in C2C12 myoblast cells. Our results clarify the essential role of PRMT1 in cardiac homeostasis and alternative splicing.

Results {#sec2}
=======

PRMT1 Is Expressed in Both Cardiomyocytes and Non-myocytes {#sec2.1}
----------------------------------------------------------

To elucidate the role of PRMT1 in the heart, we first examined the type of cells expressing PRMT1 using *Prmt1*^*tm1a\ (EUCOMM)\ Wtsi*^ knockin (PRMT1^KI^) mice ([@bib62]). *Prmt1*^*tm1a\ (EUCOMM)\ Wtsi*^ allele contains FRT-flanked *lacZ*/neomycin sequence within intron 3 in *Prmt1* gene. As PRMT1^KI^ mice express β-galactosidase (β-gal) driven by endogenous *Prmt1* promoter, we performed X-gal staining using hearts from embryos and adult mice. At embryonic day 19, β-gal activity was ubiquitously detected in the heart section, including atrial and ventricular walls ([Figure 1](#fig1){ref-type="fig"}A). In the adult mice, β-gal activity was found in the center of cardiomyocytes and in the vascular wall cells ([Figure 1](#fig1){ref-type="fig"}B). To further investigate PRMT1-expressing cell types, we examined the protein expression levels of PRMT1 in isolated primary cardiomyocytes and non-myocytes from cardiac tissues of C57BL/6 mice. Consistent with the results of X-gal staining, PRMT1 was expressed in cardiomyocytes and non-myocytes in the mouse heart ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Generation of Cardiomyocyte-Specific PRMT1-Deficient Mice(A and B) X-gal staining of (A) fetal and (B) adult hearts in PRMT1^KI^ mice. The asterisk indicates cardiac artery.(C) Western blotting of PRMT1 in neonatal mouse cardiomyocytes (CM) and non-myocytes (NM). Cardiac troponin I (cTnI) and vimentin were used as specific markers for CM and NM, respectively. GAPDH was used as loading control.(D) Schematic diagram of *Prmt1* gene targeting. Black rectangles indicate exons of *Prmt1*, and blue allows show primer set for genotyping.(E) Representative images of genotyping in PRMT1-cKO mice.(F) Western blotting analysis of PRMT1 in the hearts of control (ff/-) and PRMT1-cKO (ff/cre) mice. The hearts were harvested from 2-, 4-, and 6-week-old (shown as 2w, 4w, and 6w in the figure) mice.(G) Representative images of cardiac sections stained with anti-PRMT1 antibody (green), Hoechst 33258 (blue), anti-cardiac troponin I antibody (magenta), and WGA (gray). Arrowheads indicate nuclei of cardiomyocytes. Arrows indicate non-cardiomyocytes.

Cardiomyocyte-Specific PRMT1 Deletion Causes Dilated Cardiomyopathy in Juvenile Mice {#sec2.2}
------------------------------------------------------------------------------------

To examine the function of PRMT1 in cardiomyocytes, we generated cardiomyocyte-specific PRMT1-deficient (hereafter referred to as PRMT1-cKO) mice. These mice were obtained by crossing *Prmt1*^flox/flox^ mice with α myosin heavy chain (αMHC)-Cre transgenic mice ([Figures 1](#fig1){ref-type="fig"}D and 1E). PRMT1 protein levels were decreased in the heart of PRMT1-cKO mice compared with *Prmt1*^flox/flox^ (control) mice ([Figure 1](#fig1){ref-type="fig"}F). Immunohistochemical analysis revealed that PRMT1 is mainly expressed in the nuclei of cardiomyocytes and non-myocytes in control mice ([Figure 1](#fig1){ref-type="fig"}G, upper panels). Furthermore, in both control and cKO mice, non-myocytes showed various levels of green fluorescence, suggesting that PRMT1 expression levels are highly heterogeneous among non-myocytes depending on the cell types ([Figure 1](#fig1){ref-type="fig"}G, arrows). We found that the signals of PRMT1 were dramatically reduced in the cardiomyocytes of PRMT1-cKO mice, whereas non-myocytes normally expressed PRMT1 ([Figure 1](#fig1){ref-type="fig"}G, lower panels). These data clearly show that PRMT1 is specifically deleted in the cardiomyocytes of PRMT1-cKO mice.

To determine the influence of PRMT1 deletion on the heart, we analyzed the cardiac morphology and function in PRMT1-cKO mice. Although PRMT1-cKO mice were born in a normal Mendelian ratio (data not shown), they died within 60 days of birth ([Figure 2](#fig2){ref-type="fig"}A). Heart weight and heart/body weight ratio were significantly increased in 6-week-old PRMT1-cKO mice compared with age-matched control and *Prmt1* hetero-deficient mice ([Figures 2](#fig2){ref-type="fig"}B and 2C). PRMT1-cKO mice exhibited marked cardiac chamber dilation and fibrosis at 6 weeks of age ([Figure 2](#fig2){ref-type="fig"}D, lower panels). Cardiac systolic function of PRMT1-cKO mice began to reduce within 4 weeks after birth, and further reduction was observed in 6-week-old mice ([Figure 2](#fig2){ref-type="fig"}E). Furthermore, expression levels of βMHC (*Myh7*), ANP (*Nppa*), and BNP (*Nppb*) genes, which are well-characterized markers of heart failure, were significantly elevated in the heart of PRMT1-cKO mice at 4 weeks of age ([Figure 2](#fig2){ref-type="fig"}F).Figure 2Dilated Cardiomyopathy of PRMT1-cKO Mice(A) Survival rate of control, heterozygous (fw/cre), and PRMT1-cKO mice.(B and C) (B) Heart weight and (C) heart weight/body weight ratio (HW/BW) of 2-, 4-, and 6-week-old mice (n = 4--6).(D) H&E and Masson\'s trichrome (MT) staining of the hearts at different ages.(E) Cardiac contractility of control and PRMT1-cKO mice at different ages.(F) Gene expression analysis for marker genes of cardiac dysfunction in the heart of 4-week-old control and PRMT1-cKO mice (n = 4).All data are presented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 compared with age-matched control mice.

We further conducted a comprehensive analysis of gene expression changes in the heart of 6-week-old PRMT1-cKO mice using RNA sequencing (RNA-seq). Gene expression analysis identified 2,037 differentially expressed genes between control and PRMT1-cKO mice: 1,044 genes were upregulated and 993 genes were downregulated ([Table S1](#mmc2){ref-type="supplementary-material"}, [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Consistent with the results of histological analysis, fibrosis-related genes, such as *Tgfb2*, *Ctgf,* and collagen family, were induced in the heart of PRMT1-cKO mice ([Table S1](#mmc2){ref-type="supplementary-material"}). On the other hand, Kyoto Encyclopedia of Genes and Genomics pathway analysis of decreased genes showed an enrichment in pathways related to energy metabolism, mitochondrial function, and DCM ([Figure S1](#mmc1){ref-type="supplementary-material"}C). This transcriptional profile of the PRMT1-cKO mice coincides with that of a DCM mouse model carrying a missense mutation in the phospholamban gene ([@bib11]). These observations clearly demonstrated that juvenile PRMT1-cKO mice develop lethal DCM and that PRMT1 plays critical roles in maintaining cardiac homeostasis.

Cardiomyocyte-Specific Loss of PRMT1 Causes Aberrant Alternative Splicing of mRNA in the Heart {#sec2.3}
----------------------------------------------------------------------------------------------

To examine the effect of PRMT1 deletion on cardiac alternative splicing, we focused on the known alternative splicing events that are observed in the loss of function or the gain of function in animal models for RBPs in the heart ([Table S2](#mmc1){ref-type="supplementary-material"}), and analyzed RNA-seq data. Sashimi plots revealed differences in exon usage of several genes between control and PRMT1-cKO mice at 6 weeks of age ([Figure 3](#fig3){ref-type="fig"}A). These results were confirmed by RT-PCR using the heart of 4-week-old mice, indicating that alternative splicing abnormality occurs in the early stage of cardiac pathogenesis in PRMT1-cKO mice ([Figures 3](#fig3){ref-type="fig"}B and 3C).Figure 3Aberrant Alternative Splicing in the Heart of PRMT1-cKO Mice(A) Representative images of Sashimi plot depicting alternative splicing pattern in the heart of 6-week-old mice. Read counts for each sample are indicated on the y axis.(B and C) (B) Gel images of RT-PCR products and (C) percent spliced in (PSI) value calculated from the band intensities for assessing changes in alternative splicing in the heart of 4-week-old mice (n = 4).(D) Representative images of Sashimi plot depicting alternative splicing of *Titin* (*Ttn*) gene in the heart of 6-week-old mice. Read counts for each sample are indicated on the y axis.(E) Gel images of RT-PCR products for *Titin* gene. Blue rectangles and red lines indicate exons and introns of *Titin* gene, respectively.All data are presented as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 compared with control mice.

Alternative splicing defects or mutations of *Ttn* gene, which encodes a giant sarcomeric protein, are closely associated with DCM ([@bib26], [@bib31], [@bib56]). Consistent with a previous work using rat model ([@bib44]), intron retention was observed within the regions encoding middle Ig domains and PEVK regions in the heart of control mice, whereas it was clearly reduced in those of PRMT1-cKO mice aged 6 weeks ([Figures 3](#fig3){ref-type="fig"}D and 3E). Similar changes in alternative splicing of *Ttn* gene have been found in RBM20 knockout rats and cardiomyocyte-specific hnRNP U-deficient mice ([@bib26], [@bib44], [@bib71]). These results indicate that PRMT1 modulates cardiac alternative splicing events, regulated by a wide-range of RBPs.

The Heart of PRMT1-cKO Mouse Provides Valuable Tissues for Exploration of Unidentified Alternative Splicing Events {#sec2.4}
------------------------------------------------------------------------------------------------------------------

To further investigate the effects of PRMT1 deletion on alternative splicing in the heart, we searched for the genes that display abnormal splicing pattern in PRMT1-cKO mice. From RNA-seq data, we extracted genes that have differences in expression levels of splicing isoform between control and PRMT1-cKO mice and found 74 candidate genes ([Table S3](#mmc1){ref-type="supplementary-material"}). A gene ontology analysis of the 74 candidates showed enrichment of genes implicated in muscle development, such as muscle cell development, myofibril assembly, and actin cytoskeleton organization ([Figure S2](#mmc1){ref-type="supplementary-material"}). This hallmark was similar to that of some RBP-deficient animals ([@bib26], [@bib65], [@bib16]). Among the 74 genes, the alternative splicing of *Ttn*, *Lmo7*, *Tnnt2*, *Rtn4*, and *Obscn* has been shown to be directly regulated by RBM20 ([@bib47]). The alterations in *Pdlim5* and *Ldb3* splicing have been observed in RBM20-, RBFOX2-, and MBNL1-deficient animals ([@bib26], [@bib65], [@bib16]). In addition, alternative splicing events of *Pkm, Sptan1, Ppfibp1*, and *Popdc2* genes in the heart have already been reported ([@bib21], [@bib75], [@bib37]). Thus, these results led us to believe that our screening protocol was sensitive enough to pick up other unknown splicing events that occur in the pathologic hearts. Next, we validated those new alternative splicing events that have not been characterized in mouse hearts to date.

ASB2, a component of ECS-type (ElonginBC-Cullin-SOCS box) E3 ligase complex, has been shown to be essential for the cardiomyocyte maturation in zebrafish model ([@bib19]). In the heart of PRMT1-cKO mice, a large number of reads were detected following *Asb2* exon 6 compared with control mice, indicating the existence of the extended form of exon 6 ([Figure 4](#fig4){ref-type="fig"}A). This extended exon 6 has not been registered in the NCBI, Ensembl, or UCSC database. To verify the presence of the novel isoform of exon 6, we designed a primer set for the detection of the extended exon 6 and performed RT-PCR analysis. Although the expression level of the known transcript that includes exons 6 and 7 was slightly but significantly decreased in PRMT1-cKO mice, the extended exon 6 expression was increased in PRMT1-cKO hearts ([Figures 4](#fig4){ref-type="fig"}B and 4C). Because the extended exon 6 contains a stop codon and a putative poly(A) signal, this exon may serve as a composite terminal exon ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [@bib63]). This suggests that this novel transcript encodes truncated ASB2 protein lacking SOCS box, which is required for the formation of E3 ligase complex ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [@bib53]).Figure 4Novel Alternative Splicing Events in the Heart(A) Representative Sashimi plots depicting alternative splicing pattern in the heart of 6-week-old mice. Read counts for each sample are indicated on the y axis.(B and C) (B) Gel images of RT-PCR products and (C) relative expression (for *Asb2*) or PSI value (for *Fbxo40*, *Nrap*, and *Eif4a2*) calculated from the band intensities in the heart of 4-week-old mice (n = 4).All data are presented as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 compared with control mice.

FBXO40 is a component of SCF (Skp, Cullin, and F box) E3 ligase complex, modulating insulin-like growth factor 1 (IGF1) receptor signaling pathway via ubiquitination of IRS1 in skeletal muscle ([@bib59]). A large part of FBXO40 coding sequence is encoded by exon 3 (Ensembl Transcript ID: ENSMUST00000075869.12). Although most of the *Fbxo40* mRNA was contained in exon 3 in the control hearts, exon 3 skipping was significantly increased in the PRMT1-cKO hearts ([Figures 4](#fig4){ref-type="fig"}A--4C).

*Nrap* (nebulin-related anchoring protein) gene encodes a cytoskeletal protein ([@bib3]). It has been reported that the expression of NRAP is upregulated in mouse models of DCM ([@bib18]). Furthermore, several studies investigated the alternative splicing of *Nrap* exon 12 included in skeletal muscle isoform, but not in cardiac isoform ([@bib51], [@bib6]). In addition to exon 12, the NCBI database suggests that *Nrap* exon 2 is alternatively spliced (NM_001286552.1); however, this splicing event has not been characterized in the heart. Although alternative splicing defect of *Nrap* has been found in the heart of *Rbfox2*-KO mice, a model of DCM, which exons are affected by *Rbfox2* deficiency in the heart has not been addressed ([@bib65]). We found that exon skipping of *Nrap* exon 2, encoding an LIM domain of NRAP protein, was significantly increased in PRMT1-cKO mice ([Figures 4](#fig4){ref-type="fig"}A--4C).

*Eif4a2* gene encodes eIF4A2 DEAD-box RNA helicase associated with translation initiation, microRNA-mediated gene repression, and stress granule formation ([@bib50], [@bib36]). A previous report demonstrated that knockdown of splicing factor U2AF65 or U2AF35 induces the inclusion of a 107-nucleotide (nt) exon of *EIF4A2* in HeLa cells ([@bib58]). Importantly, the exon-intron structure of eIF4A2 gene is highly conserved between human and mouse ([Figure S3](#mmc1){ref-type="supplementary-material"}B, a--c). In the PRMT1-cKO mice, the 107-nt exon inclusion of *Eif4a2* was significantly increased compared with control mice ([Figures 4](#fig4){ref-type="fig"}A--4C).

Taken together, we discovered previously unrecognized cardiac alternative splicing events through the use of PRMT1-cKO mice.

eIF4A2 Isoforms Are Differentially Ubiquitinated and Degraded in C2C12 Cells {#sec2.5}
----------------------------------------------------------------------------

Finally, we explored the significance of alternative splicing of *Eif4a2* under more physiological conditions. It has been reported that *Eif4a2* mRNA expression is increased in differentiating C2C12 mouse myoblast cells, and that double knockdown of *Eif4a1* and *Eif4a2* suppresses myoblast differentiation into myotubes ([@bib20]). The differentiation process of C2C12 cells is intimately involved in alternative splicing ([@bib9], [@bib60]), whereas the association between alternative splicing of *Eif4a2* and C2C12 differentiation is undefined. Therefore, we investigated whether C2C12 differentiation is linked to alternative splicing change of *Eif4a2*. We found that the undifferentiated C2C12 cells predominantly expressed long *Eif4a2* transcripts ([Figure 5](#fig5){ref-type="fig"}A). Furthermore, the long *Eif4a2* isoform expression was reduced in differentiating C2C12 cells, whereas that of the short *Eif4a2* isoform was markedly increased ([Figure 5](#fig5){ref-type="fig"}A). Although changes in alternative splicing of *Eif4a2* were found in PRMT1-deficient hearts ([Figure 4](#fig4){ref-type="fig"}) and U2AF knockdown cells ([@bib58]), data suggested that these splicing changes were also induced by physiological stimuli, such as myoblast differentiation.Figure 5Differential Ubiquitination Status of eIF4A2 Isoforms(A) RT-PCR analysis for detecting *Eif4a2* alternative splicing in undifferentiated and differentiated C2C12 cells.(B) Schematic diagrams of *Eif4a2* pre-mRNA 3′ end, C-terminal sequences of eIF4A2, and eIF4A2 protein domains.(C) Western blot analysis of HA-eIF4A2 wild-type (wt) and truncated (tr) isoforms in C2C12 cells 24 hr after transfection. β-Actin was used as a loading control.(D) Immunoprecipitation assay for detecting ubiquitination of HA-eIF4A2 isoforms in C2C12 cells. At 16 hr after transfection, cells were treated with MG132 (10 μM) for 8 hr.

The NCBI database predicts that the long *Eif4a2* transcript (NR_110335.1), upregulated in the heart of PRMT1-cKO mice ([Figure 4](#fig4){ref-type="fig"}), is a candidate for nonsense-mediated mRNA decay (NMD). Indeed, the 107-nt exon of long *Eif4a2* transcript contains a premature termination codon (PTC) positioned more than 50--55 nt upstream of the last exon-exon junction ([Figure 5](#fig5){ref-type="fig"}B). However, several reports have demonstrated that the PTC-containing transcript escapes NMD, and is translated into a truncated protein that plays an important physiological role ([@bib33], [@bib2], [@bib17]). Furthermore, our data showed that PTC-containing long *Eif4a2* transcript is expressed at substantial levels in the heart of PRMT1-cKO mice and in undifferentiated C2C12 cells ([Figures 4](#fig4){ref-type="fig"}B and [5](#fig5){ref-type="fig"}A), suggesting that long *Eif4a2* transcript is translated into truncated eIF4A2 protein ([Figure 5](#fig5){ref-type="fig"}B). Although eIF4A2 possesses motif VI, which probably functions as a trigger of ATP hydrolysis, at its C terminus ([@bib54], [@bib57]), truncated eIF4A2 isoform partially lacks motif VI ([Figure 5](#fig5){ref-type="fig"}B).

To investigate the functional difference of eIF4A2 isoforms, expressed differentially in the heart of control and PRMT1-cKO mice, we generated hemagglutinin (HA)-tagged eIF4A2 (HA-eIF4A2-wt) and HA-tagged truncated-eIF4A2 (HA-eIF4A2-tr) expression vectors. Although equivalent amount of vectors was transfected into C2C12 cells, unexpectedly, the protein level of HA-eIF4A2-tr was remarkably lower than that of HA-eIF4A2-wt ([Figure 5](#fig5){ref-type="fig"}C). A previous study showed that eIF4A2 protein is sumoylated on K226 in mammalian cells ([@bib36]), whereas some proteomic analyses indicated that eIF4A2 protein contains several ubiquitination sites ([@bib15], [@bib39]; curated information is available on PhosphoSitePlus, a database of post-translational modifications). Therefore, we hypothesized that HA-eIF4A2-tr protein is ubiquitinated and degraded by the ubiquitin-proteasome system. To examine this hypothesis, we treated C2C12 cells with MG132 after transfection and assessed the ubiquitination levels of HA-eIF4A2 isoforms. MG132 treatment increased both HA-eIF4A2-wt and HA-eIF4A2-tr protein levels ([Figure 5](#fig5){ref-type="fig"}D, input). Furthermore, poly-ubiquitination of HA-eIF4A2-wt and HA-eIF4A2-tr was detected in MG132-treated C2C12 cells ([Figure 5](#fig5){ref-type="fig"}D, immunoprecipitation \[IP\]: HA). It is noteworthy that HA-eIF4A2-tr protein was highly ubiquitinated compared with HA-eIF4A2-wt ([Figure 5](#fig5){ref-type="fig"}D, IP: HA), indicating that the 47 amino acid residues in the C terminus of eIF4A2-wt protect against ubiquitination and subsequent degradation by the ubiquitin-proteasome system.

Discussion {#sec3}
==========

In the present study, we generated cardiomyocyte-specific PRMT1-deficient mice and demonstrated the vital role of PRMT1 in maintaining cardiac function. Moreover, cardiac alternative splicing was disturbed in the heart of PRMT1-cKO mice, indicating the critical role of PRMT1 in the regulation of alternative splicing *in vivo*. In addition, using this animal model, we successfully detected novel alternative splicing products in the heart.

PRMT1 Is Essential for Cardiac Development in Mice {#sec3.1}
--------------------------------------------------

Accumulating evidence demonstrates that PRMT1, a dominant type I PRMT in mammalian cells, controls tissue development, regeneration, and homeostasis *in vivo* ([@bib29], [@bib8]). In the present study, we showed that cardiomyocyte-specific deletion of PRMT1 provoked DCM in juvenile mice. Although PRMT1 has been suggested to be involved in the pathogenesis of heart diseases via overproduction of free asymmetric dimethylarginine followed by its nitric oxide synthase (NOS)-inhibiting effect ([@bib28], [@bib45]), our data clearly demonstrated that PRMT1 has essential roles in cardiac development and homeostasis under physiological conditions. Despite the parallel expression of PRMT1 in cardiomyocytes and non-myocytes, PRMT1 deficiency in cardiomyocytes led to DCM in juvenile mice, demonstrating an indispensable role of arginine methylation catalyzed by PRMT1 in cardiomyocytes.

Association between PRMT1 and Cardiac Splicing Regulation {#sec3.2}
---------------------------------------------------------

In the postnatal heart, many physiological and structural changes occur, becoming fully functional by adulthood. Although these processes are transcriptionally regulated, alternative splicing also participates in postnatal cardiac development ([@bib4]). Interestingly, it has been demonstrated that the majority of alternative splicing transitions in cardiomyocytes occur during the first 4 weeks after birth in mice ([@bib23]). In the present study, we found that PRMT1-cKO mice showed cardiac alternative splicing defects and reduction of cardiac contractility at 4 weeks after birth. We therefore postulated that alternative splicing transition fails in PRMT1-cKO mice. Indeed, we showed that exon skipping of *Tmed2* and *Snap23* was significantly increased in 4-week-old PRMT1-cKO mice ([Figures 3](#fig3){ref-type="fig"}B and 3C); these splicing patterns resemble the feature in neonatal hearts ([@bib23]). These observations suggest that PRMT1 regulates alternative splicing transition in the postnatal hearts.

In this study, we found and validated the four novel splicing events in the heart ([Figure 4](#fig4){ref-type="fig"}). Among these, we discovered a new *Asb2* isoform that is not registered in the NCBI, Ensemble, or UCSC database. This novel *Asb2* transcript, which has the extended exon 6 containing a stop codon and a putative poly(A) signal, seems to encode truncated ASB2 protein that lacks SOCS box, suggesting the failure to form E3 ligase complex. On the other hand, ankyrin repeat, a putative substrate recognition motif ([@bib43], [@bib1]), partially remained in truncated ASB2 protein. Therefore, this truncated ASB2 might function as a dominant-negative isoform to trap substrates. To detect the truncated ASB2 protein, we used commercially available anti-ASB2 antibody that is raised against the N-terminal of ASB2. We were unable to confirm the expression of truncated ASB2 protein in cardiac lysate, whereas weak signal from the full-length ASB2 protein was seen (data not shown), probably because of a lower expression level of truncated ASB2 than full-length protein. Since the expression level of novel *Asb2* isoform was increased in the PRMT1-deficient hearts, PRMT1 may be involved in determining alternative polyadenylation sites in the cardiomyocytes.

Although splicing events of three other genes (*Fbxo40*, *Nrap*, and *Eif4a2*) are recorded in at least one database, there is no evidence demonstrating that these splicing events actually occur in the hearts. It has been reported that FBXO40, a component of SCF E3 ligase complex, regulates IGF1 signaling in the skeletal muscle ([@bib59]). FBXO40 is also expressed in human and rodent hearts ([@bib72]), but its function remains unclear. We found that skipping of the exon encoding a large part of FBXO40 protein was significantly increased in the PRMT1-cKO heart ([Figures 4](#fig4){ref-type="fig"}B and 4C). The Ensembl database predicts that this transcript does not contain an open reading frame, suggesting that this short form of *Fbxo40* transcript exists as long non-coding RNA (lncRNA). Interestingly, a recent study revealed that lncRNA, which is produced by alternative splicing of protein-coding gene, plays an important role in tumor progression ([@bib24]). This raises the possibility that lnc-*Fbxo40* has pathophysiological roles in the heart, and PRMT1 acts as a molecular switch to regulate *Fbxo40* gene function. However, further studies are needed to confirm whether the short form of *Fbxo40* transcript functions as an lncRNA.

We showed that the usage of *Nrap* exon 2 was significantly decreased in the heart of PRMT1-cKO mice ([Figures 4](#fig4){ref-type="fig"}B and 4C). *Nrap* transcript that lacks exon 2 encodes an NRAP protein deficient for the LIM domain. NRAP is dominantly expressed in cardiac and skeletal muscles, and is upregulated in the heart of DCM mouse models ([@bib3]). NRAP is localized in Z-disk precursors during myofibrillogenesis, whereas specific localization of NRAP at the intercalated disks is found in the adult heart ([@bib3]). A previous report revealed that the LIM domain of NRAP strongly binds to talin: talin binds the cytoplasmic domain of β1D integrin subunit, whereas NRAP super-repeats bind to actin, suggesting that NRAP is a component of the protein complex that anchors actin filaments to the plasma membrane ([@bib46]). Although integrin and talin are mainly localized in the costamere, they are also found at the intercalated disks in the heart ([@bib35], [@bib48]). Interestingly, a recent study demonstrated that talin1/talin2 double knockout mice exhibit DCM ([@bib49]). These observations suggest that increase in NRAP lacking the LIM domain may affect the mechanotransduction system through the absence of binding to integrin and talin in the intercalated disks and may contribute to cardiac pathogenesis. Because the role of integrin system in the intercalated disks is largely unknown, it is interesting to investigate the implication in *Nrap* isoform shift and the function of NRAP lacking LIM domain in the heart.

It has been shown that knockdown of splicing factor U2AF increases the 107-nt exon inclusion of *EIF4A2* in HeLa cells ([@bib58]). In the present study, we found that this 107-nt exon of mouse *Eif4a2* is alternatively spliced in the heart and C2C12 cells, suggesting that alternative splicing of *Eif4a2* occurs under physiological conditions in the cardiac and skeletal muscle cells. We assumed that long *Eif4a2* transcript encodes truncated eIF4A2 protein and examined its protein function. Unexpectedly, we found that the eIF4A2 protein is constantly ubiquitinated, and that the truncated isoform is more efficiently ubiquitinated and degraded than the eIF4A2-wt protein, indicating that the splicing switch of *Eif4a2* may regulate its protein levels utilizing the ubiquitin-proteasome system. It has been reported that eIF4A is overexpressed in lung and cervical cancer, and inhibitors of eIF4A have antitumor activity ([@bib7]). Therefore, an understanding of the molecular basis for alternative splicing and ubiquitination of eIF4A2 may provide new insight into the pathogenesis of heart failure, muscle differentiation, and cancer therapy.

PRMT1 Is a Possible Upstream Regulator of RBPs {#sec3.3}
----------------------------------------------

In the past decade, a number of studies have revealed the critical roles of the RBPs in the cardiac alternative splicing regulation by analyzing genetically engineered mice. On the other hand, we showed that deletion of PRMT1 impairs the cardiac alternative splicing of a broad spectrum of genes, including already reported genes that are affected by the deletion or mutation of RBPs. These observations raise the possibility that PRMT1 participates in alternative splicing regulation through the methylation of RBPs in the cardiomyocytes. It has been reported that cardiomyocyte-specific deletion of hnRNP U (also known as SAF-A) results in splicing defects and severe DCM ([@bib71]). Importantly, a previous report demonstrated that PRMT1 methylates hnRNP U, whereas arginine methylation of hnRNP U did not affect its nuclear localization ([@bib32]). SRSF1 (as known as SF2/ASF) deficiency in cardiomyocytes also contributes to aberrant splicing and DCM ([@bib67]). Although which PRMTs are involved is unknown, arginine methylation controls SRSF1 nuclear localization ([@bib61]). Furthermore, proteomic analyses suggested that other RBPs that are related to the cardiac alternative splicing, such as RBFOX1, RBFOX2, MBNL1, and SRSF10, have putative arginine methylation sites ([@bib25], [@bib41], [@bib22]). Our results suggest that PRMT1 may serve as a key regulator of RBPs functions, such as nuclear localization, RNA-binding properties, and binding of other splicing factors, in the cardiomyocytes.

Taken together, our findings identify an essential role of PRMT1 in the cardiac alternative splicing *in vivo*, and the heart of PRMT1-cKO mouse is an effective tool for understanding the relationship between alternative splicing regulation and heart failure.

Limitations of the Study {#sec3.4}
------------------------

In the present study, we showed that PRMT1 deficiency in cardiomyocytes causes aberrant alternative splicing in the heart. As it is currently not known whether the changes in alternative splicing are due to direct effects of PRMT1 deficiency or secondary consequences (e.g., an influence of DCM), we examined the effect of PRMT1 knockdown on alternative splicing of *Eif4a2* in C2C12 cells. However, we were unable to accurately assess the contribution of PRMT1 to *Eif4a2* splicing in undifferentiated or differentiated C2C12 cells (data not shown). This may be because knockdown of PRMT1 was inefficient for changing *Eif4a2* alternative splicing, or PRMT1 regulates alternative splicing in a cell-type-dependent manner. Therefore, other experimental models are needed to investigate whether the changes in alternative splicing are due to the lack of PRMT1.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Software Availability {#appsec3}
==============================

The accession number for the data reported in this study is GEO: [GSE112938](ncbi-geo:GSE112938){#intref0190a}.
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Document S1. Transparent Methods, Figures S1--S3, and Tables S2 and S3Table S1. A Full Gene List of Differentially Expressed Genes between Control and PRMT1-cKO Mice, Related to Figure 3
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